Aniz Girach, MD, is joining ProQR in the role of Chief Medical Officer Tiffany Burtis joining the Company in the role of Vice president, Head of Commercial Lisa Hayesis joining the Company in the role of Vice President of Investor Relations and Corporate Communications Smital Shahis promoted to Chief Business and Financial Officer
- René Beukema will retire at year-end 2018 as Chief Corporate Development Officer & General Counsel and management board member
Robert Cornelisse, Chief People and Organizationwill also retire at year-end 2018
“We are excited to announce several changes to our team, setting up our company for its next phase. With the addition of Aniz’s decades of experience in ophthalmology I’m confident we can accelerate our pipeline for patients with inherited retinal disease, in LCA10, Usher syndrome and beyond,” said
“I am grateful to René and Robert for their important contributions to establishing, building and growing our company over the last five years,” continued Daniel.
At year-end 2018 both René Beukema, Chief Corporate Development Officer, General Counsel and management board member and
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the
Vice President of Investor Relations and Corporate Communications
T: +1 202 360 4855
LifeSci Public Relations
T: +1 646 876 4933
Source: ProQR Therapeutics N.V.